Literature DB >> 3010854

Incorporation of 1-beta-D-arabinofuranosylcytosine into DNA and mutagenesis of herpes simplex virus type 1.

G J Bubley, C S Crumpacker, L E Schnipper.   

Abstract

To investigate the association between incorporation of 1-beta-D-arabinofuranosylcytosine (ara-C) into herpes simplex virus type 1 (HSV-1) DNA and mutagenesis at selected genetic loci, we grew virus in the presence or absence of ara-C and compared the mutation frequencies. Both the forward mutation frequency of HSV-1 (KOS) to the tk- phenotype and the reversion frequency of a temperature-sensitive mutant to the non-temperature-sensitive (ts+) phenotype were significantly increased following growth in ara-C. When the same viruses were grown in an inhibitor of the HSV-1 DNA polymerase that is not incorporated into DNA, no significant increase in the frequency of tk- or ts+ particles was observed. Furthermore, HSV-1 araAr, a mutant resistant to ara-C on the basis of reduced incorporation of the analog into viral DNA, did not demonstrate an increase in the number of tk- particles following growth in ara-C. These results suggest that mutagenesis of HSV-1 following growth in ara-C correlates with incorporation of the nucleoside analog into viral DNA.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3010854      PMCID: PMC180475          DOI: 10.1128/AAC.29.4.716

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  33 in total

1.  1-beta-D-arabinofuranosylcytosine-induced malignant transformation of hamster and rat cells in culture.

Authors:  R E Kouri; S A Kurtz; P J Price; W F Benedict
Journal:  Cancer Res       Date:  1975-09       Impact factor: 12.701

2.  Interallelic complementation of mutants of herpes simplex virus deficient in deoxypyrimidine kinase activity.

Authors:  A T Jamieson; J H Subak-Sharpe
Journal:  Virology       Date:  1978-03       Impact factor: 3.616

3.  Bioassay program for carcinogenic hazards of cancer chemotherapeutic agents.

Authors:  E K Weisburger
Journal:  Cancer       Date:  1977-10       Impact factor: 6.860

4.  Induction of malignant transformation and mutagenesis in cell cultures by cancer chemotherapeutic agents.

Authors:  H Marquardt; H Marquardt
Journal:  Cancer       Date:  1977-10       Impact factor: 6.860

5.  Transformation of hamster cells in vitro by 1- -D arabinofuranosylcytosine, 5-fluorodeoxyuridine and hydroxyurea.

Authors:  P A Jones; J V Taderera; A O Hawtrey
Journal:  Eur J Cancer       Date:  1972-12       Impact factor: 9.162

6.  The mutagenicity to mammalian cells of pyrimidine nucleoside analogs.

Authors:  E Huberman; C Heidelberger
Journal:  Mutat Res       Date:  1972-01       Impact factor: 2.433

7.  Comparison of conformational characteristics of arabinose and ribose containing dinucleoside phosphates.

Authors:  J C Maurizot; W J Wechter; J Brahms; C Sadron
Journal:  Nature       Date:  1968-07-27       Impact factor: 49.962

8.  Cytogenetic and morphologie abnormalities in human bone marrow cells during cytosine arabinoside therapy.

Authors:  W R Bell; J J Whang; P P Carbone; G Brecher; J B Block
Journal:  Blood       Date:  1966-06       Impact factor: 22.113

9.  Inhibition of DNA polymerase-alpha and -beta of calf thymus by 1-beta-D-arabinofuranosylcytosine-5'-triphosphate.

Authors:  S Yoshida; M Yamada; S Masaki
Journal:  Biochim Biophys Acta       Date:  1977-07-15

10.  Genome locations of temperature-sensitive mutants in glycoprotein gB of herpes simplex virus type 1.

Authors:  N DeLuca; S Person; D J Bzik; W Snipes
Journal:  Virology       Date:  1984-09       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.